TRESK Channel Activation Reduces Migraine Pain by Blocking CGRP Release From Nerve Endings | Research

The takeaway

The TRESK channel activator cloxyquin reduced migraine-like pain, CGRP release, and mast cell degranulation in rat models, with effects abolished by a specific TRESK inhibitor and synergistic with sumatriptan.

TRESK → CGRP↓
TRESK channel activation reduces CGRP release across multiple migraine-relevant brain and nerve structures

What the researchers found

TRESK activation by cloxyquin reduced CGRP release, allodynia, and mast cell degranulation in migraine models, with all effects specifically blocked by TRESK inhibitor A2764 and synergistic with sumatriptan ex vivo.

Why it matters

CGRP-targeting drugs have revolutionized migraine treatment, but not all patients respond. TRESK channels offer an upstream mechanism to reduce CGRP release, potentially helping patients who don't benefit from current CGRP-blocking therapies.

The numbers in context

Multiple dose levels of cloxyquin tested; compared against sumatriptan (established migraine drug) and A2764 (TRESK inhibitor) in various combinations.

How the study worked

In vivo nitroglycerin-induced migraine model and ex vivo meningeal, trigeminal ganglion, and brainstem preparations in rats, testing TRESK activator cloxyquin, TRESK inhibitor A2764, and sumatriptan alone and in combinations.

Who was studied

Rats in nitroglycerin-induced migraine models

What this study cannot tell us

Animal model results may not fully translate to human migraine; cloxyquin is not a clinically approved drug; synergistic effect seen ex vivo but not in vivo; specific TRESK activators for human use need development; single migraine model tested.

How to read the evidence

Preliminary preclinical evidence with strong mechanistic validation (specific inhibitor controls), but no human data available.

When this study was published

Published in 2024, representing emerging research into novel ion channel targets for migraine treatment.

The bigger picture

TRESK channels represent a new therapeutic target upstream of CGRP in the migraine cascade. Activating these channels could provide an alternative or complementary approach to the current wave of CGRP-targeting antibodies and antagonists.

Questions still open

Can selective TRESK activators be developed for safe human use?
Would TRESK activation benefit migraine patients who don't respond to CGRP-targeting drugs?
Why did the synergistic effect with sumatriptan appear ex vivo but not in vivo?

Common questions

What are TRESK channels and how do they relate to migraines?

TRESK channels are potassium channels found in migraine-relevant nerve cells. When activated, they reduce the release of CGRP — the same pain-promoting peptide targeted by newer migraine drugs. This offers a new way to reduce CGRP activity from a different angle.

Could this lead to new migraine medications?

Potentially — the study showed TRESK activators can reduce migraine-like symptoms in rats and even work synergistically with sumatriptan. The next step is developing selective TRESK activators safe for human use.

Read the original research

TRESK channel activation ameliorates migraine-like pain via modulation of CGRP release from the trigeminovascular system and meningeal mast cells in experimental migraine models.

Life sciences, 357, 123091

View on PubMed ↗Publisher’s paper ↗

Citation

Torun, Ibrahim Ethem; Kilinc, Yasemin Baranoglu; Kilinc, Erkan; Töre, Fatma. (2024). TRESK channel activation ameliorates migraine-like pain via modulation of CGRP release from the trigeminovascular system and meningeal mast cells in experimental migraine models.. Life sciences, 357, 123091. https://doi.org/10.1016/j.lfs.2024.123091